Mutant p53-Stabilizing Compounds for Tumor Suppressor Reactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells evade apoptosis through suppression of p53 function, leading to uncontrolled proliferation and metastasis, and existing treatments fail to effectively restore wild-type p53 activity in mutant p53 proteins.
Innovation Solution
Compounds that selectively bind to mutant p53 proteins, stabilizing them and restoring wild-type p53 activity, thereby activating downstream tumor suppression pathways such as apoptosis, cell cycle arrest, and senescence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used to treat cancer, then cancer cells can be targeted, but wild-type p53 activity cannot be effectively restored in mutant p53 proteins
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of p53-binding compounds to specifically target and stabilize mutant p53 proteins. The compounds alter the conformational state and binding properties of mutant p53, restoring its wild-type activity through structural parameter modification rather than relying on existing treatment mechanisms.
Solution Approach 2:
The patent introduces intermediary compounds that act as mediators between the mutant p53 protein and the therapeutic effect. These compounds bind to mutant p53, stabilize its structure, and restore its tumor-suppressing function, serving as a bridge that converts the inactive mutant form into an active therapeutic agent.
2Reliability
If mutant p53 proteins are stabilized, then wild-type p53 activity is restored, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent extracts the essential function of wild-type p53 and applies it to mutant p53 through selective stabilization compounds. By isolating and targeting the specific structural defects in mutant p53, the treatment restores the essential tumor suppression function without requiring complex multi-component therapies.
Solution Approach 2:
The patent creates functional copies of wild-type p53 activity within mutant p53 proteins. The compounds induce conformational changes that replicate the binding and transcriptional activation properties of wild-type p53, effectively copying its functional output in the mutated protein context.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds enhance the ability of mutant p53 to bind DNA and activate downstream effectors, leading to increased apoptosis, cell cycle arrest, and senescence in cancer cells, providing a therapeutic approach to inhibit cancer progression.
Implementation Method 1
the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant p53 protein
Implementation Method 2
leading to increased apoptosis, cell cycle arrest, and senescence in cancer cells
Data Source
AI summary
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.